Last reviewed · How we verify
Dihydroartemisinin-Piperaquine drug combination
Dihydroartemisinin-Piperaquine, marketed by the University of Yaounde 1, is an established antimalarial drug combination. The key composition patent expires in 2028, providing a significant period of market exclusivity. The primary risk is the lack of detailed revenue data and key trial results, which may limit strategic planning and investor confidence.
At a glance
| Generic name | Dihydroartemisinin-Piperaquine drug combination |
|---|---|
| Also known as | D-ARTEPP dispersible |
| Sponsor | University of Yaounde 1 |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults (PHASE1)
- Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria (PHASE4)
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- Mass Vaccine and Drug Administration, Bangladesh (PHASE4)
- Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials (PHASE2, PHASE3)
- Safety of Antimalarials in the FIRst trimEster (PHASE3)
- Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: